

OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2022-01-19 17:53:07

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	African horse sickness
Address of laboratory:	(LCV) Ctra. M-106 pk 1,4 28110 Algete.Madrid (Spain) (UCM) Avda. de Puerta de Hierro s/n 28040. Madrid (Spain)
Tel.:	(LCV)+34 913478312
Fax:	(LCV) +34 913473778
E-mail address:	maguerog@mapa.es
Website:	(LCV) https://www.mapa.gob.es/en/ganaderia/temas/laboratorios/referencia-union-europea-oie/default.aspx (UCM) www.sanidadanimal.info
Name (including Title) of Head of Laboratory (Responsible Official):	(LCV)Dr. Montserrat Agüero Garcia (UCM)Prof. José Manuel Sánchez-Vizcaíno
Name (including Title and Position) of OIE Reference Expert:	(LCV) Dr. Montserrat Agüero Garcia (UCM) Prof. José Manuel Sánchez-Vizcaíno
Which of the following defines your laboratory? Check all that apply:	Governmental Academic

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
(LCV) ELISA bloqueo	SI	722 muestras (158 plan de vigilancia + 154 movimientos équidos + 400 preparación Ensayo intercomparación EURL + 10 Participación Ensayo intercomparación EURL)	3 muestras como EURL: procedente de Bélgica
(LCV) SNT	SI		3 muestras como EURL: procedente de Bélgica
Direct diagnostic tests			
(LCV) RRT-PCR Agüero et al; 2008 (VP7)	SI	260 muestras (250 preparación Ensayo intercomparación EURL + 10 Participación Ensayo intercomparación EURL)	
(LCV) RRT-PCR multiplex específicas de serotipo (VP2)	NO	225 muestras (15x9 serotipos Ensayo intercomparación EURL + 10x9 Participación Ensayo intercomparación EURL)	

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

African horse sickness - Montserrat Agüero Garcia - Spain

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
(LCV)VPEA de los serotipos 1, 4 y 6 inactivados. Enviados en el ensayo de intercomparación organizado por el EU-RL	RT-PCR	20 ml/virus inactivado	600µl/muestra (10 muestras/participante)	600µl/muestra (10 muestras/participante)	22 EU-NRLs (Luxembourg and Estonia that do not take part in the Proficiency Test and Cyprus, Lithuania and Malta that do not participate in the RT-PCR panel) + Morocco (2 labs), Tunisia, Turkey, Switzerland, Norway, United Kingdom, Spain, Mexico, Canada, Singapore, Thailand, India, Kirguistan, Myanmar, United Arabs Emirates and South Africa (3 labs)	<input checked="" type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input checked="" type="checkbox"/> Middle East
(LCV) sueros equinos de animales vacunados frente al serotipo 4 del VPEA, de animales infectados naturalmente y experimentalmente y de caballos negativos enviados en el ensayo de intercomparación organizado por el EU-RL	ELISA	30 ml/suero	300µl/muestra (10 muestras/participante)	300µl/muestra (10 muestras/participante)	25 EU-NRLs (Luxembourg and Estonia do not take part in the Proficiency Test) + Morocco (2 labs), Tunisia, Argelia, Turkey, Switzerland, Norway, United Kingdom (2 labs), Spain (2 labs), Mexico, Canada, Singapore, Thailand, India, Kirguistan, United Arabs Emirates (2 labs) and South Africa (2 labs)	<input checked="" type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input checked="" type="checkbox"/> Middle East
(LCV) sueros ovino frente a los serotipos 1, 4 y 7 de animales infectados experimentalmente enviados en el ensayo de intercomparación organizado por el EU-RL	Seroneutralization	30 ml/suero	500µl/muestra (8 muestras/participante)	500µl/muestra (8 muestras/participante)	Austria, France, Italy, Neatherlands, Spain, United Kingdom, Morocco, South Africa (2 labs) and Thailand.	<input checked="" type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

VPEA-1 THA 2020, VPEA-2 ETH2010/01y VPEA-7 KEN 2015 (DUBAI)	RT-PCR			1 ml/cepa	Spain	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
sueros 260 (sero1), 261 (sero2) y 271 (sero7)	Seroneutralization			1 ml/suero	Spain	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
VPEA-1 THA2020	RT-PCR			1 ml	France	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
9 sueros positivos ovinos de los 9 serotipos producidos experimentalmente frente al VPEA	Seroneutralización			1 ml/suero	Austria	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
BELGIUM	Enero	-	3 muestras de suero

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

No

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

No

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

No

If the answer is no, please provide a brief explanation of the situation:
-

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:
-

**13. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 0

b) International conferences: 1

AHS&BT EURL Annual meeting

Rubén Villalba: AHS EURL Activities 2021

c) National conferences: 0

d) Other:

(Provide website address or link to appropriate information) 1

(LCV)<https://www.mapa.gob.es/en/ganaderia/temas/laboratorios/referencia-union-europea-oie/default.aspx>

(UCM)<https://www.sanidadanimal.info/es/>

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
(UCM) ISO 17025	817_LE1410.pdf
(LCV) UNE EN ISO 17025	5-.certificado Acreditacion ENAC_LE-1530_02.08.2018_sello electronico.pdf
(LCV) UNE EN ISO 14001	3-.CertificadoGA-2002-0327_ES_2020-11-06.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
(UCM) Detección del virus de la peste porcina africana (PPA) mediante PCR en tiempo real	ENAC
(LCV) Detección de anticuerpos frente al VPEA mediante ELISA en sueros de équidos	ENAC
(LCV) Detección de orbivirus mediante cultivo celular (BTV, AHSV, EHDV) en muestras de sangre completa no coagulada, bazo, pulmón y nódulos linfáticos	ENAC
(LCV) Detección-identificación del VPEA mediante RT-PCR a tiempo real en muestras de vísceras de animales, sangre y cultivos celulares	ENAC
(LCV) Serotipificación de anticuerpos frente a Orbivirus por neutralización (BTV, AHSV, EHDV) en suero de rumiantes y équidos	ENAC
(LCV) Tipificación del VPEA mediante RT-PCR a tiempo real en muestras de vísceras de animales, sangre y cultivos celulares	ENAC

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals*, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: ¹	Role of your Reference Laboratory (organiser/participant)	No. participants	Participating OIE Ref. Labs/organising OIE Ref. Lab.
(LCV) Ensayo interlaboratorial	Organizador/participante	48	Lab. Ref. OIE organizador: LCV (Spain) Lab. Ref. OIE AHS Participantes: -The Pirbright Institute (UK) - LCV (Spain) - OVI (South Africa)

¹ validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
(LCV)Organización de un ensayo de intercomparación, como EU-RL, de aptitud para la evaluación de métodos de diagnóstico (detección de anticuerpos y genoma viral)	48	<input checked="" type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input checked="" type="checkbox"/> Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report:

Nuestros expertos consultores están siempre a disposición de la OIE